Fig. 1

Transcriptional aberrations identified in CAMs in GBM predict the pro-tumorigenic potential of PTGFRN in GBM. A Volcano graph depicting upregulated (red), downregulated (green), and unregulated (black) CAMs in GBM samples (n = 572) as compared to control samples (n = 10). The horizontal line separates the CAMs having a significant difference in expression (p-value≤0.05). Vertical lines show the cut-off value ≤− 0.58 or ≥0.58 log₂ ratio for classifying differentially regulated CAMs. B Kaplan-Meier curve shows the overall survival difference between PTGFRN-high and low transcript groups of GBM. Scatter plots show the transcript level of PTGFRN in GBM in - C TCGA Agilent, TCGA RNA-Seq, and REMBRANDT, D TCGA GBM subtypes: classical, mesenchymal, neural, and proneural, E mut-IDH1 and wt-IDH1, G-CIMP+ and G-CIMP–, and MGMT methylated and MGMT unmethylated groups. F Immunohistochemical (IHC) analysis for PTGFRN in GBM tissues, percent tumor cell positivity is indicated, G quantification shows percent tumor cell positivity in a given number of tissues samples. H Bar graph shows transcript level of PTGFRN in GBM cell lines and immortalized human astrocytes (SVG and IHA), and control brain samples as measured by RT-qPCR. I Immunoblot shows protein level of PTGFRN in GBM cell lines and immortalized human astrocytes and β-Actin served as a loading control (required portion of the blot is shown after cropping from the whole blot for both the proteins). The normalized protein levels are shown in the bar diagram. The significance was tested using the Wilcoxon-Mann-Whitney test and the symbols are indicated as follows: (ns) not significant; (*) p ≤ 0.05; (**) p ≤ 0.01 and (***) p ≤ 0.001